Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain buoyant
Mon, 22 Oct 01:30 pm

Indian share markets continued to trade above the dotted line in the post-noon trading session. Majority of the sectoral indices are trading negative with FMCG, realty, and consumer durables stocks leading the pack of losers. IT, pharma and banking stocks are among the few gainers.

BSE-Sensex is up 48 points and NSE-Nifty is trading up 11 points. While BSE Mid Cap Index is marginally down, BSE Small Cap index is up 0.2%. The rupee is trading at 53.6 to the US dollar.

Most of the food stocks are trading in the positive led by Godfrey Phillips and Tata Global beverages. ITC has announced its results for the second quarter ended September 2012. The company posted a 20% growth in sales led by strong double-digit growth in both its FMCG and agri businesses. In FMCG, the cigarette segment grew by 14% whereas the non-cigarette FMCG segment comprising of packaged foods, personal care products and stationary products grew by a faster 26%. Agri business reported a 41% jump in revenues aided by wheat exports. However, paper and hotel business segments clocked single-digit growth in revenues during the quarter. Aided by controlled staff costs and other expenses, the company's operating margin improved by 70 basis points (0.7%) to 37.2%. Among business segments, only cigarettes and paper businesses have expanded their EBIT margin in 2QFY13. Hotel business saw its EBIT margin shrink by more than half to 7%. The non-cigarette FMCG segment pared losses from Rs 559 m in the year-ago quarter to Rs 303 m. Earnings increased by 21% for the quarter backed by healthy growth in operating income and lower tax incidence.ITC stock is down 2%.

Majority of the domestic pharma stocks are trading positive with Aurobindo Pharma and Divi's Laboratories being the biggest gainers. As reported by a leading business daily, Dr. Reddy's has announced its interest in buying OctoPlus, Amsterdam for an offer price of about £ 27.4 m or Rs 1.9 bn. This amount would give Dr. Reddy's outright or 100% stake in OctoPlus. This price is believed to be offered at a premium of 30% to the closing price of October 19. OctoPlus is a service based specialty pharmaceutical company. As reported by Dr. Reddy's management, this deal would help the company ramp up its technological capabilities. The company intends to build its research base in Leiden (Netherlands). This acquisition is slated to take place by the end of the current fiscal year and would be an all cash deal. Dr. Reddy's stock is up 1.3%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.